Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials

被引：0

作者：

Clowse, Megan E. B. ^{[1
]}

Wallace, Daniel J. ^{[2
]}

Furie, Richard ^{[3
]}

Petri, Michelle ^{[4
]}

Pike, Marilyn ^{[5
]}

Leszczynski, Piotr ^{[6
]}

Neuwelt, C. Michael ^{[7
]}

Hobbs, Kathryn ^{[8
]}

Keiserman, Mauro ^{[9
]}

Duca, Liliana ^{[10
]}

Kalunian, Kenneth ^{[11
]}

Bongardt, Sabine ^{[12
]}

Stach, Christian ^{[12
]}

Beaudot, Carolyn ^{[13
]}

Kilgallen, Brian ^{[13
]}

Galateanu, Catrinel ^{[14
]}

Gordon, Caroline ^{[15
,16
]}

机构：

[1] Duke Univ, Rheumatol, Durham, NC USA

[2] Cedars Sinai Med Ctr, Div Rheumatol, Los Angeles, CA 90048 USA

[3] North Shore LIJ Hlth Syst, Manhasset, NY USA

[4] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

[5] Med Pharm Consulting Inc, Cambridge, MA USA

[6] Poznan Univ Med Sci, J Strus Poznan Municipal Hosp, Dept Rheumatol & Clin Immunol, Poznan, Poland

[7] Alameda Cty Med Ctr, Div Rheumatol, Oakland, CA USA

[8] Denver Arthrit Clin, Denver, CO USA

[9] Pontifical Cathol Univ, Sch Med, Porto Alegre, RS, Brazil

[10] Clin Neomed, Brasov, Romania

[11] UCSD Sch Med, La Jolla, CA USA

[12] UCB Pharma, Monheim, Germany

[13] UCB Pharma, Raleigh, NC USA

[14] UCB Pharma, Brussels, Belgium

[15] Univ Birmingham, Rheumatol Res Grp, Sch Immun & Infect, Coll Med & Dent Sci, Birmingham, W Midlands, England

[16] Univ Hosp Birmingham NHS Fdn Trust, NIHR Wellcome Trust Clin Res Facil, Birmingham, W Midlands, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Clowse, Megan E. B.
Wallace, Daniel J.
Furie, Richard A.
Petri, Michelle A.
Pike, Marilyn C.
Leszczynski, Piotr
Neuwelt, C. Michael
Hobbs, Kathryn
Keiserman, Mauro
Duca, Liliana
Kalunian, Kenneth C.
Galateanu, Catrinel
Bongardt, Sabine
Stach, Christian
Beaudot, Carolyn
Kilgallen, Brian
Gordon, Caroline
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 362 - 375
[2] Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study
Tsuru, Tomomi
Tanaka, Yoshiya
Kishimoto, Mitsumasa
Saito, Kazuyoshi
Yoshizawa, Seiji
Takasaki, Yoshinari
Miyamura, Tomoya
Niiro, Hiroaki
Morimoto, Shinji
Yamamoto, Junichi
Lledo-Garcia, Rocio
Shao, Jing
Tatematsu, Shuichiro
Togo, Osamu
Koike, Takao
[J]. MODERN RHEUMATOLOGY, 2016, 26 (01) : 87 - 93
[3] Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Wallace, Daniel J.
Gordon, Caroline
Strand, Vibeke
Hobbs, Kathryn
Petri, Michelle
Kalunian, Kenneth
Houssiau, Frederic
Tak, Paul P.
Isenberg, David A.
Kelley, Lexy
Kilgallen, Brian
Barry, Anna N.
Wegener, William A.
Goldenberg, David M.
[J]. RHEUMATOLOGY, 2013, 52 (07) : 1313 - 1322
[4] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Wallace, Daniel J.
Kalunian, Kenneth
Petri, Michelle A.
Strand, Vibeke
Houssiau, Frederic A.
Pike, Marilyn
Kilgallen, Brian
Bongardt, Sabine
Barry, Anna
Kelley, Lexy
Gordon, Caroline
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 183 - 190
[5] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials
Silverberg, Jonathan
Thaci, Diamant
Seneschal, Julien
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric
Chu, Chia-Yu
Liu, Zhuqing
Lima, Renata Gontijo
Pillai, Sreekumar
Guttman-Yassky, Emma
[J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 62 - 62
[6] Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Furie, Richard A.
Bruce, Ian N.
Doerner, Thomas
Leon, Manuel Gustavo
Leszczynski, Piotr
Urowitz, Murray
Haier, Birgit
Jimenez, Teri
Brittain, Claire
Liu, Jiajun
Barbey, Catherine
Stach, Christian
[J]. RHEUMATOLOGY, 2021, 60 (11) : 5397 - 5407
[7] SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EPRATUZUMAB IN JAPANESE PATIENTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PHASE 1/2 STUDY
Yamamoto, J.
Lledo-Garcia, R.
Tsuru, T.
Tanaka, Y.
Koike, T.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 526 - 526
[8] Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Morand, Eric
Furie, Richard
Tanaka, Yoshiya
Bruce, Ian
Askanase, Anca
Riche'z, Christophe
Bae, Sang-Cheol
Brohawn, Philip
Pineda, Lilia
Berglind, Anna
Tummala, Raj
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
[9] EFFICACY AND SAFETY OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF THE SECOND PHASE 3 RANDOMIZED CONTROLLED TRIAL
Morand, Eric F.
Furie, Richard
Tanaka, Yoshiya
Bruce, Ian N.
Askanase, Anca D.
Richez, Christophe
Bae, Sang-Cheol
Brohawn, Mr Philip Z.
Pineda, Lilia
Berglind, Anna
Tummala, Raj
[J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 22 - 23
[10] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
Silverberg, Jonathan I.
Thaci, Diamant
Seneschal, Julien
Gold, Linda Stein
Blauvelt, Andrew
Simpson, Eric
Chu, Chia-Yu
Liu, Zhuqing T.
Lima, Renata Gontijo
Pillai, Sreekumar
Guttman-Yassky, Emma
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98

← 1 2 3 4 5 →